Merit Medical Systems
NASDAQ: MMSI
$74.30 ▲ +1.19  (+1.63%)
At close: Jul 24, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap4.42 Bn
P/E152.93
P/S2.87
Div. Yield0.00
ROIC (Qtr)0.22
Total Debt (Qtr)735.16 Mn
Revenue Growth (1y) (Qtr)7.46
Add ratio to table…

About

Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary medical devices used in interventional diagnostic and therapeutic procedures particularly in cardiology radiology oncology critical care and endoscopy. We strive to be the most customer focused company in healthcare. Each day we are determined to make a difference by understanding our customer needs and innovating and delivering a diverse range of products that improve the lives of people and…

Read more ↓
Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000856982

Investment Thesis

▲ Bull case
  • Merit Medical Systems, Inc. is positioned for sustained margin expansion and profitable growth through its strategic shift toward higher-margin therapeutic products, with oncology emerging as a key growth engine due to the Viewpoint Medical acquisition. The company's new reporting structure highlights that therapeutic products grew at an 11% compound annual growth rate over the last three years on an organic basis, significantly outpacing foundational products' 6% CAGR. This shift is not merely incremental but structural, as therapeutic products now represent a higher-value, higher-margin segment of the business. The Viewpoint acquisition, which adds the OneMark detection imaging system and tissue markers, directly expands Merit's addressable oncology market from approximately 300,000 SCOUT-eligible procedures annually to over 1.3 million breast biopsy procedures in the U.S. alone—a nearly fourfold increase in addressable opportunity. Management explicitly stated that this expansion is driven by serving lower-risk patients who were previously underserved by SCOUT's radar technology, creating a complementary rather than cannibalistic product offering. Crucially, the acquisition is projected to deliver 20%+ annual sales growth for OneMark with 70% non-GAAP gross margins and operating margins above the company average, which will meaningfully uplift consolidated profitability as the business scales. The market is underestimating how quickly this integration can drive cross-selling opportunities, as Merit's existing oncology field force can now offer both SCOUT and OneMark, increasing wallet share per account without proportional increases in sales headcount. This strategic fit allows for rapid market penetration, particularly as physician preference splits between radar (SCOUT) and ultrasound (OneMark) technologies create a dual-pathway adoption model that enhances customer retention and reduces competitive vulnerability. Furthermore, the company's disciplined approach to tuck-in acquisitions—focusing on strategic platforms with margin accretion and commercial footprint leverage—suggests that Viewpoint is not an isolated move but the beginning of a broader oncology platform expansion strategy, with additional tuck-ins likely in adjacent diagnostic and localization markets. The market's current valuation does not fully reflect the margin accretion potential from this strategic shift, especially as tariff headwinds are expected to moderate and the DualCap divestiture removes a low-margin drag on gross margins.
  • Merit Medical Systems, Inc. possesses underappreciated operating leverage and financial flexibility that will support continued earnings growth and shareholder returns despite near-term macroeconomic uncertainties. The company generated $25 million in free cash flow in Q1 FY26, a 26% year-over-year increase, demonstrating strong conversion of earnings into cash even while absorbing $4.6 million in tariff impacts and funding the Viewpoint acquisition. This cash generation capability is underpinned by a net leverage ratio of 1.6x, leaving approximately $697 million of available borrowing capacity, which provides substantial flexibility for additional strategic tuck-ins, debt reduction, or share repurchases should the board choose to pursue them. Management explicitly noted that they are conserving cash for M&A opportunities but highlighted that their free cash flow generation remains robust, with the Viewpoint acquisition projected to be only $0.05 dilutive to 2026 non-GAAP EPS and accretive by the twelve months ending December 31, 2027. This timeline suggests that the market is underestimating the speed at which acquired businesses can integrate and contribute to earnings, particularly given Viewpoint's projected high gross and operating margins. Furthermore, the company's operating model reorganization around eight co-led platforms (each with a marketing and R&D lead) has improved cross-functional alignment and accountability, which is already yielding benefits in segments like Endoscopy (mid-teens Q1 growth) and Cardiac Therapies. This structural improvement enhances innovation velocity and commercial execution without requiring proportional increases in SG&A, as evidenced by Q1 operating expenses increasing only 5% despite revenue growth of 5% and a 47 basis point year-over-year increase in non-GAAP operating margin to 19.7%—the highest first-quarter margin in company history. The market is overlooking how this operating discipline, combined with the divestiture of low-margin DualCap (which removed approximately $20 million in annual revenue and a gross margin drag), is creating a higher-quality revenue base. With tariff impacts expected to be resolved or refunded in part—as management indicated they have already filed for reimbursement and feel optimistic about recovering the $15 million annual impact—the company's earnings potential is likely understated in current guidance, which still assumes a full $15 million tariff drag through 2026. Any reduction in this assumed impact would directly flow to the bottom line, providing upside to EPS guidance that is not currently priced in.
▼ Bear case
  • Merit Medical Systems, Inc. faces significant near-term headwinds in its OEM business that are being underestimated by management and could persist beyond transient timing issues, posing a material risk to overall revenue growth and margin stability. While Raul Parra characterized Q1 OEM sales declines of 14% year-over-year as transient or timing-based due to inventory destocking related to product line transfers to Tijuana, Mexico, and noted improving early Q2 order trends, the persistence of this weakness raises concerns about underlying demand deterioration, particularly in the APAC region. Management acknowledged that sales to OEM customers outside the U.S. continue to be impacted by the macro environment, especially in APAC, and while they cited APAC up 1% constant currency in Q1 (beating guidance), this masks significant regional disparities—China sales were up only 2% constant currency, in line with expectations but indicative of continued weakness under volume-based purchasing (VBP) pressures. The company's own guidance assumes low single-digit growth for China in 2026, suggesting that the OEM business's normalized mid-to-high single-digit growth profile may be overly optimistic if VBP reforms continue to squeeze pricing and utilization in key international markets. Furthermore, the OEM segment's contribution to total revenue is not trivial; while not explicitly quantified in the transcript, historical context implies it is a meaningful portion of the foundational products business, which comprises two-thirds of total revenue. Persistent weakness here could offset strength in therapeutic products and undermine the company's ability to achieve its guided mid-single-digit constant currency growth for foundational products. The market is ignoring the risk that OEM is not merely a capacity play but a critical feedback loop for product innovation and commercialization—if demand from OEM partners weakens, it could signal broader market softness or competitive displacement that may eventually affect Merit's branded businesses. Additionally, the Medtronic distribution deal, while cited as a positive for OEM confidence, remains undefined in terms of stocking commitments or growth impact, creating uncertainty about whether this represents a sustainable recovery or another temporary bump in an otherwise declining trend.
  • Merit Medical Systems, Inc.'s reliance on tuck-in acquisitions as a primary growth driver introduces execution and integration risks that are not being adequately disclosed, particularly regarding the Viewpoint Medical acquisition and its projected financial contributions, which may be overly optimistic given the company's historical acquisition pacing and the complexity of integrating ultrasound-based diagnostics into an established radar-centric oncology platform. While management projects Viewpoint to contribute $2 million to $4 million in revenue for the remainder of 2026 and accrete to non-GAAP EPS by the twelve months ending December 31, 2027, this timeline assumes seamless integration and rapid market adoption—yet the OneMark system represents a different technology paradigm (ultrasound-enhanced tissue markers) compared to Merit's legacy SCOUT radar platform, requiring retraining of sales teams, updates to clinical protocols, and potential physician education efforts. The transcript reveals that OneMark was previously running a head-to-head trial against SCOUT, the outcome of which could influence future product positioning and internal resource allocation—yet management dismissed strategic implications by stating it is merely a matter of physician preference, overlooking the potential for internal conflict or cannibalization if one technology gains clear clinical or economic advantages. Furthermore, the company's acquisition history shows a pattern of tuck-ins (BioLife, C2 Cryo Balloon) that exceeded expectations in Q1, but these were smaller, more complementary deals; Viewpoint at $140 million enterprise value is significantly larger and represents a material step-up in deal size, increasing integration complexity and execution risk. The guidance assumes Viewpoint will dilute 2026 non-GAAP EPS by $0.05 but be accretive by late 2027—a window that leaves little room for integration delays, which are common in med-tech acquisitions involving new technology adoption and clinical workflow changes. If integration slips or market adoption lags, the acquisition could remain dilutive longer than projected, weighing on EPS and forcing a reevaluation of the company's capital allocation priorities. The market is not pricing in the risk that Merit's aggressive M&A pace, while strategically sound, could strain operational capacity or lead to cultural misalignment, especially as the company attempts to scale its commercial footprint across eight distinct platforms without a proportional increase in centralized oversight.

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 ALC Alcon Inc 33,163,703.85 Bn498,335.123.14 Mn4.16 Bn
2 ISRG Intuitive Surgical Inc 119.67 Bn37.900.00 Mn-
3 BDX Becton Dickinson & Co 43.92 Bn37.380.00 Mn17.28 Bn
4 MDLN Medline Inc. 31.71 Bn56.520.00 Mn12.57 Bn
5 RMD Resmed Inc 28.46 Bn18.730.00 Mn0.66 Bn
6 WST West Pharmaceutical Services Inc 23.80 Bn45.050.00 Mn0.20 Bn
7 COO Cooper Companies, Inc. 13.77 Bn58.380.00 Mn2.46 Bn
8 SOLV Solventum Corp 13.63 Bn9.510.00 Mn5.08 Bn